|
|
|
|
Repros Therapeutics Provides Update For Proellex Clinical Program
Proellex for the treatment of dysmenorrhea, non-menstrual pelvic pain and dyspareunia Repros Therapeutics has an end of phase II meeting scheduled with FDA in September, to discuss a phase III program investigating the use of Proellex...
|
|
|
June 2009 Briefing - Ophthalmology
Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for June 2009.This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes...
|
|
|
Repros Therapeutics Inc. (RPRX) to Stop Using 50 mg Dose in Fibroids Study
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqGM:RPRX - News) announced today that an end of Phase II meeting is scheduled with the Food and Drug Administration (FDA) for late September 2009 to discuss a Phase III program...
|
|
|
Repros Therapeutics Inc. Provides Update for Proellex Clinical Program
- Repros Therapeutics (NasdaqGM:RPRX) announced today that an end of Phase II meeting is scheduled with the Food and Drug Administration (FDA) for late September 2009 to discuss a Phase III program investigating the use of Proellex in the...
|
|
|
Repros Therapeutics Inc. Provides Update for Proellex Clinical Program
- Repros Therapeutics (NasdaqGM:RPRX) announced today that an end of Phase II meeting is scheduled with the Food and Drug Administration (FDA) for late September 2009 to discuss a Phase III program investigating the use of Proellex in the...
|
|
|
Repros Therapeutics Inc. Provides Update for Proellex Clinical Program
The Phase II study that Repros completed earlier this year demonstrated clinically and statistically significant reductions of the three key pain symptoms commonly experienced by women with endometriosis: dysmenorrhea (painful menses),...
|
|
|
Repros Therapeutics Inc. Provides Update for Proellex Clinical Program
Repros Therapeutics (NasdaqGM:RPRX) announced today that an end of Phase II meeting is scheduled with the Food and Drug Administration (FDA) for late September 2009 to discuss a Phase III program investigating the use of Proellex in the...
|
|
|
BioElectronics Provides Recap of Conference Call
FREDERICK, MD -- (MARKET WIRE) -- 06/19/09 -- BioElectronics Corp.(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today provided its investors with a summary of the conference call held after...
|
|
|
BioElectronics Provides Recap of Conference Call
BioElectronics Corp.(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today provided its investors with a summary of the conference call held after the market closed on Thursday, June 18th. On...
|
|
|
BioElectronics Is Filing For 510(k) Clearance With FDA For Its AllayTM Product
Women's Health / Gynecology News Main Category: Women's Health / Gynecology Also Included In: Regulatory Affairs / Drug Approvals email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public...
|
|
|
BioElectronics Announces Investor Conference Call
BioElectronics Corp.(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced its management team will host an investor conference call to discuss its recent application for FDA...
|
|
|
BioElectronics Is Filing for 510(k) Clearance With FDA for Its Allay(TM) Product
FREDERICK, MD -- (MARKET WIRE) -- 06/15/09 -- BioElectronics Corp.(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it is filing an application with the U.S. Food and Drug...
|
|
|
BioElectronics Is Filing for 510(k) Clearance With FDA for Its Allay(TM) Product
FREDERICK, MD -- (MARKET WIRE) -- 06/15/09 -- BioElectronics Corp.(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it is filing an application with the U.S. Food and Drug...
|
|
|
BioElectronics Is Filing for 510(k) Clearance With FDA for Its Allay(TM) Product
BioElectronics Corp.(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it is filing an application with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to...
|
|
|
What is the 5-year cumulative failure rate of global endometrial ablation?
(Click the title below to leave the MDLinx Network and go to the Journal's Website) APCToday, 05/29/09 Bradley LD - 16% of women who underwent global endometrial ablation for AUB needed hysterectomy or repeat ablation for bleeding or pain...
|
|
|
Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS
(Click the title below to leave the MDLinx Network and go to the Journal's Website) International Journal of Women's Health, 05/27/09 Print Save in My Library Free Full Text Bednarek PH et al.- The levonorgestrel-releasing intrauterine...
|
